Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Inventiva S.A.NASDAQ: IVA

Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025

Selling, general & admin grows 317.9% year over year

Q4 FY2025 selling, general & admin of €37.27M rose 317.9% year over year. Over 3 fiscal years it compounded at +51.5% a year.

Context

  • Selling, general & admin amounted to 1202.1% of revenue in FY2025, up 1016.2 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 9 analysts of €13.83M (-74.3%) for the fiscal year ending Dec 2026, a slowdown from the +215.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
€37.27M— QoQ
Last fiscal yearDec 2025
€53.89M+215.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+317.9%——
1 year+215.2%-74.3%-289.5 pp
3-year CAGR+51.5%+108.0%+56.5 pp
5-year CAGR+112.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

EUR · from the income statement

Latest · FY2025
53.89M EUR
Year-over-year change
+215.2%
4-year CAGR
+47.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +215.2% is the highest of 10, against a peer median of +4.4%.
  • Selling, general & admin amounts to 1202.1% of revenue for IVA, versus a peer median of 323.5%.
IVA Competitors
Selling, General & Admin for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$74.78M USD+14.7%+12.5%133.9%
IVAInventiva S.A.FY2025€53.89M EUR+215.2%+51.5%1202.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$38.28M USD-25.4%-1.1%55.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$36.25M USD-1.5%-0.1%323.5%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$30.27M USD+4.4%+9.7%1705.2%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$26.99M USD+11.1%+24.6%82.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$24.19M USD+23.5%+3.4%41000.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$23.71M USD-4.5%+3.4%10537.3%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$23.69M USD+2.7%+2.7%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$17.83M USD+52.6%+62.5%—
Peer median (excluding IVA) —+4.4%+3.4%323.5%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.19M12.18M17.48M9.2M4.48M
Cost of Revenue1.02M995K(23K)3.88M2.8M
Gross Profit4.19M17.06M17.5M9.2M1.51M
Gross Margin100.0%140.1%100.1%100.0%33.7%
Research & Development48.45M60.47M110.01M90.88M83.61M
Selling, General & Admin11.52M15.5M15.61M17.1M53.89M
Operating Expenses56.31M74.17M120.19M106.76M137.37M
Depreciation & Amortization858K870K2.6M5.2M2.8M
EBITDA(52.76M)(56.29M)(102.04M)(166.53M)(128.15M)
EBITDA Margin-1258.0%-462.2%-583.9%-1810.4%-2858.6%
Operating Income(52.11M)(57.11M)(102.71M)(97.56M)(130.95M)
Operating Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%
Interest Income57K390K945K1.14M2.83M
Interest Expense138K707K5.18M12.18M32.3M
Other Income / Expenses2.84M2.82M(7.11M)(86.34M)(211.38M)
Income Before Tax(49.27M)(54.29M)(109.82M)(183.9M)(342.33M)
Pre-Tax Margin-1174.8%-445.8%-628.4%-1999.4%-7636.1%
Income Tax Expense364K(20K)607K313K22K
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Net Margin-1183.5%-445.6%-631.8%-2002.7%-7587.8%
EPS (Basic)(1.27)(1.31)(2.43)(3.54)(1.82)
EPS (Diluted)(1.27)(1.31)(2.43)(3.54)(1.82)
Weighted Avg Shares39.17M41.45M45.35M51.98M186.8M
Weighted Avg Shares (Diluted)39.17M41.45M45.35M51.98M186.8M

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.